Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ADPT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $4.52B
- EPS (TTM)
- -$0.45
- Dividend yield
- None
- 52-week range
- 12.00 – 32.21
- Day range
- 27.15 – 28.23
- Volume / Avg
- 2.48M / 2.20M
- Beta
- —
- Shares outstanding
- 161.88M
52-week range
ADPT stock today
Shares of Adaptive Biotechnologies (ADPT) finished lower on Nov 20 at $27.93, a drop of 0.43% or $0.12 per share, versus the S&P 500's 3.70% decline. Shares are 13.3% below their 52-week high of $32.21, set on Nov 11, 2026 and 132.8% above the 52-week low of $12.00, in the middle of the past year's range. ADPT is up 72.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 50.1%.
Adaptive Biotechnologies has posted a net loss over the last twelve months (EPS of -$0.45), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Adaptive Biotechnologies
Company profileAdaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD).
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Chad M. Robins M.B.A.
- Headquarters
- Seattle, WA
- Employees
- 624
- IPO year
- 2019
- Website
- adaptivebiotech.com
Financial highlights
Full financialsIn fiscal 2025, Adaptive Biotechnologies generated $277.0 million in revenue, up 54.8% from fiscal 2024, its 2nd consecutive year of revenue growth. Adaptive Biotechnologies reported a net loss of $59.5 million, compared with a loss of $159.5 million a year earlier. Gross margin was 74.2% (up from 59.7%) and operating margin -20.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $276.98M | $178.96M | $170.28M | $185.31M | $154.34M |
| Growth | +54.77% | +5.10% | -8.11% | +20.06% | +56.88% |
| Net income | $-59.50M | $-159.49M | $-225.25M | $-200.19M | $-207.28M |
| EPS (diluted) | $-0.39 | $-1.08 | $-1.56 | $-1.40 | $-1.48 |
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$33.86+21.23%
- Strong buy 2
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $0.02 vs $-0.10
- Surprise
- +120.00%
ADPT news
All ADPT news- FDA Grants Priority Tag to AZN's BLA Filing for Gastric Cancer DrugNasdaqAZN, ADPT, SMMT, ACIU
- Sanofi's Next-Generation Rabies Vaccine Secures Approval in EUNasdaqSNY, ADPT, ACIU, AMRX
- SNY Wins FDA Approval for Infilbray in Type 3 Gaucher DiseaseNasdaqSNY, ADPT, ACIU, AMRX
- GSK Wins FDA Approval for Nuvalent-Acquired Nelkarmi in Lung CancerNasdaqGSK, ADPT, ACIU, AMRX
- Adaptive Biotechnologies Highlights clonoSEQ’s Central Role in Advancing MRD-Guided Care Across Hematology at ASH 2026GlobeNewswire
- Summit Stock Falls on FDA Rejection for Lung Cancer DrugNasdaqSMMT, ADPT, ACIU, AMRX
- REPL Stock Up 80% in a Month on Tudriqev Launch & Pipeline ProgressNasdaqREPL, BMY, ADPT, ACIU
- Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch ReliefNasdaqZTS, ADPT, ACIU, AMRX
Adaptive Biotechnologies peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CRSPCRISPR Therapeutics AG | 39.10 | +0.44% | $3.79B | vs ADPT |
| TARSTarsus Pharmaceuticals Inc. | 73.01 | -6.00% | $3.60B | vs ADPT |
| RLAYRelay Therapeutics Inc. | 16.12 | +1.32% | $3.56B | vs ADPT |
| SRRKScholar Rock Holding Corporation | 48.13 | -4.45% | $5.87B | vs ADPT |
| IOVAIovance Biotherapeutics Inc. | 6.90 | -5.61% | $3.19B | vs ADPT |
| DNLIDenali Therapeutics Inc. | 18.45 | +1.37% | $2.96B | vs ADPT |
| VCELVericel Corporation | 57.52 | -1.27% | $2.94B | vs ADPT |
| ADMAADMA Biologics Inc | 13.17 | -1.27% | $2.92B | vs ADPT |
Indexes, lists and sector
Adaptive Biotechnologies stock FAQ
What is Adaptive Biotechnologies's stock price today?
ADPT last traded at $27.93 as of Nov 20, 4:00 PM EST, down 0.43% on the day. Prices are delayed at least 15 minutes.
Who is Adaptive Biotechnologies's CEO?
Mr. Chad M. Robins M.B.A. is the chief executive officer of Adaptive Biotechnologies Corporation, which has about 624 employees.
What is the ADPT 52-week high?
The 52-week high for ADPT is $32.21 and the 52-week low is $12.00. The stock is currently 13.3% below its high.